Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nabilone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 known ✓ | P21554 | 12/20 | 1.00 |
| ▸ | CNR2 | P34972 | 14/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nabilone SCHEMBL17223864 | 1.00 | CNR2 (1.00) | CNR2CNR1NR1I2ADORA3SLC6A3 | |
| Nabilone SCHEMBL11268571 | 1.00 | CNR2 (1.00) | CNR2CNR1NR1I2ADORA3SLC6A3 | |
| Nabilone SCHEMBL33339 | 1.00 | CNR2 (1.00) | CNR2CNR1NR1I2ADORA3SLC6A3 | |
| SCHEMBL11615666 | 1.00 | CNR2 (1.00) | CNR2CNR1NR1I2ADORA3SLC6A3 | |
| Nabilone SCHEMBL29475614 | 1.00 | CNR2 (1.00) | CNR2CNR1NR1I2ADORA3SLC6A3 | |
| Nabilone SCHEMBL29448222 | 1.00 | CNR2 (1.00) | CNR2CNR1NR1I2ADORA3SLC6A3 | |
| Nabilone SCHEMBL15520922 | 1.00 | CNR2 (1.00) | CNR2CNR1NR1I2ADORA3SLC6A3 | |
| Nabilone SCHEMBL13759779 | 1.00 | CNR2 (1.00) | CNR2CNR1NR1I2ADORA3SLC6A3 | |
| Nabilone SCHEMBL563809 | 1.00 | CNR2 (1.00) | CNR2CNR1NR1I2ADORA3SLC6A3 | |
| SCHEMBL11615083 | 0.99 | CNR2 (0.98) | CNR2CNR1NR1I2ADORA3SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4075230-A | Preparation of optically active trans-hexahydrodibenzopyranones | ELI LILLY AND COMPANY (US) | 1978-02-21 | — | — | US | claimed |
| WO-2024145493-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NABILONE FOR THE TREATMENT OF OPHTHALMIC CONDITIONS | ADTECH PHARMA, INC. (US) | 2024-07-04 | — | — | WO | disclosed |
| US-20230210786-A1 | METHOD FOR SOLUBILIZING NATURAL, ENDOGENOUS AND SYNTHETIC CANNABINOIDS | ATHENION AG (CH) | 2023-07-06 | — | — | US | disclosed |
| US-11670410-B1 | Systems and methods to automatically administer a psychoactive substance to an airway of a user based on a detected event or condition | Green Sky Creations LLC (US) | 2023-06-06 | — | — | US | disclosed |
| US-11670410-B1 | Systems and methods to automatically administer a psychoactive substance to an airway of a user based on a detected event or condition | Green Sky Creations LLC (US) | 2023-06-06 | — | — | US | disclosed |
| EP-4157215-A1 | METHOD FOR SOLUBILIZING NATURAL, ENDOGENOUS AND SYNTHETIC CANNABINOIDS | Athenion AG (CH) | 2023-04-05 | — | — | EP | disclosed |
| US-11464758-B2 | Cannabinoid co-drug compounds | KOTZKER CONSULTING LLC (US) | 2022-10-11 | — | — | US | disclosed |
| US-20220151981-A1 | USE OF CANNABINOIDS AND TERPENES FOR TREATMENT OF ORGANOPHOSPHATE AND CARBAMATE TOXICITY | KOTZKER CONSULTING LLC (US) | 2022-05-19 | — | — | US | disclosed |
| US-11266623-B2 | Use of cannabinoids and terpenes for treatment of organophosphate and carbamate toxicity | KOTZKER CONSULTING LLC (US) | 2022-03-08 | — | — | US | disclosed |
| US-20210393575-A1 | N-ACYLATED FATTY AMINO ACIDS TO REDUCE ABSORPTION VARIABILITY IN CANNABINOID BASED COMPOSITIONS | RECEPTOR HOLDINGS, INC. (US) | 2021-12-23 | — | — | US | disclosed |
| US-20100298579-A1 | Process for preparing synthetic cannabinoids | THC PHARM GMBH (DE) | 2010-11-25 | — | — | US | disclosed |
| US-20100168086-A1 | 7,8,10,10A-TETRAHYDRO-6H-BENZO[C]CHROMEN-9(6AH)-ONE MODULATORS OF CANNABINOID RECEPTORS | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-07-01 | — | — | US | disclosed |
| US-20060074101-A1 | Method of treating post operative nausea and vomiting | HELSINN HEALTHCARE SA (CH) | 2006-04-06 | — | — | US | disclosed |
| US-4208351-A | Stereoselective preparation of hexahydro dibenzopyranones and intermediates therefor | ELI LILLY AND COMPANY (US) | 1980-06-17 | — | — | US | disclosed |
| US-4195025-A | 9-Amino-dibenzopyrans | ELI LILLY AND COMPANY (US) | 1980-03-25 | — | — | US | disclosed |
| US-4176233-A | Stereoselective preparation of hexahydro dibenzopyranones and intermediates therefor | ELI LILLY AND COMPANY (US) | 1979-11-27 | — | — | US | disclosed |
| EP-0003883-A1 | Amino-dibenzopyrans, their preparation, formulations containing them and their use as pharmaceuticals | ELI LILLY AND COMPANY (US) | 1979-09-05 | — | — | EP | disclosed |
| US-4152450-A | 9-Amino-dibenzopyrans | ELI LILLY AND COMPANY (US) | 1979-05-01 | — | — | US | disclosed |
| US-4102902-A | Stereoselective preparation of hexahydro dibenzopyranones and intermediates therefor | ELI LILLY AND COMPANY (US) | 1978-07-25 | — | — | US | disclosed |
| US-4075230-A | Preparation of optically active trans-hexahydrodibenzopyranones | ELI LILLY AND COMPANY (US) | 1978-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168086-A1 | 7,8,10,10A-TETRAHYDRO-6H-BENZO[C]CHROMEN-9(6AH)-ONE MODULATORS OF CANNABINOID RECEPTORS | CNR1, CNR2, GPR18 | CNR1 1/4885CNR2 2/4885NR1I2 264/4885 |
| US-11464758-B2 | Cannabinoid co-drug compounds | ACHE, CNR2, CNR1 | CNR1 3/4885CNR2 2/4885NR1I2 808/4885 |
| US-20060074101-A1 | Method of treating post operative nausea and vomiting | HTR3A, HTR3C, HTR5A | CNR1 102/4885CNR2 77/4885NR1I2 2396/4885 |
| US-20210393575-A1 | N-ACYLATED FATTY AMINO ACIDS TO REDUCE ABSORPTION VARIABILITY IN CANNABINOID BASED COMPOSITIONS | FAAH, CNR2, FABP2 | CNR1 5/4885CNR2 2/4885NR1I2 1840/4885 |
| US-20100298579-A1 | Process for preparing synthetic cannabinoids | CNR2, CNR1, FAAH | CNR1 2/4885CNR2 1/4885NR1I2 2185/4885 |
| US-20220151981-A1 | USE OF CANNABINOIDS AND TERPENES FOR TREATMENT OF ORGANOPHOSPHATE AND CARBAMATE TOXICITY | ACHE, BCHE, CNR2 | CNR1 4/4885CNR2 3/4885NR1I2 756/4885 |
| US-11266623-B2 | Use of cannabinoids and terpenes for treatment of organophosphate and carbamate toxicity | ACHE, BCHE, CNR1 | CNR1 3/4885CNR2 4/4885NR1I2 858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.